<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Regulatory Approval Expenses Archives - Bhatt &amp; Joshi Associates</title>
	<atom:link href="https://bhattandjoshiassociates.com/tag/regulatory-approval-expenses/feed/" rel="self" type="application/rss+xml" />
	<link></link>
	<description>Best High Court Advocates &#38; Lawyers</description>
	<lastBuildDate>Mon, 16 Nov 2026 10:34:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bhattandjoshiassociates.com/wp-content/uploads/2025/08/cropped-bhatt-and-joshi-associates-logo-32x32.png</url>
	<title>Regulatory Approval Expenses Archives - Bhatt &amp; Joshi Associates</title>
	<link></link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Capital vs Revenue Expenditure: Tax Treatment of Product Registrations, Trade Marks and Regulatory Approvals</title>
		<link>https://bhattandjoshiassociates.com/capital-vs-revenue-expenditure-tax-treatment-of-product-registrations-trade-marks-and-regulatory-approvals/</link>
		
		<dc:creator><![CDATA[Komal Ahuja]]></dc:creator>
		<pubDate>Mon, 16 Nov 2026 10:34:09 +0000</pubDate>
				<category><![CDATA[Income Tax]]></category>
		<category><![CDATA[Capital vs Revenue Expenditure]]></category>
		<category><![CDATA[Depreciation on Intangible Assets]]></category>
		<category><![CDATA[Enduring Benefit Test]]></category>
		<category><![CDATA[Income Tax Act]]></category>
		<category><![CDATA[Product Registration Expenses]]></category>
		<category><![CDATA[Regulatory Approval Expenses]]></category>
		<category><![CDATA[Section 37(1)]]></category>
		<guid isPermaLink="false">https://bhattandjoshiassociates.com/?p=57415</guid>

					<description><![CDATA[<p>A pharmaceutical manufacturer closes its books for the year with three payments recorded on the same page of its ledger. The question of whether these payments constitute capital or revenue expenditure under income tax law determines whether they can be deducted against current profits or must be capitalised and potentially depreciated. The first is a [&#8230;]</p>
<p>The post <a href="https://bhattandjoshiassociates.com/capital-vs-revenue-expenditure-tax-treatment-of-product-registrations-trade-marks-and-regulatory-approvals/">Capital vs Revenue Expenditure: Tax Treatment of Product Registrations, Trade Marks and Regulatory Approvals</a> appeared first on <a href="https://bhattandjoshiassociates.com">Bhatt &amp; Joshi Associates</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p dir="ltr"><img fetchpriority="high" decoding="async" class="alignnone  wp-image-57418" src="https://bhattandjoshiassociates.com/wp-content/uploads/2026/11/Capital-vs-Revenue-Expenditure-Tax-Treatment-of-Product-Registrations-Trade-Marks-and-Regulatory-Approvals-300x157.jpg" alt="Capital vs Revenue Expenditure Tax Treatment of Product Registrations, Trade Marks and Regulatory Approvals" width="1511" height="791" srcset="https://bhattandjoshiassociates.com/wp-content/uploads/2026/11/Capital-vs-Revenue-Expenditure-Tax-Treatment-of-Product-Registrations-Trade-Marks-and-Regulatory-Approvals-300x157.jpg 300w, https://bhattandjoshiassociates.com/wp-content/uploads/2026/11/Capital-vs-Revenue-Expenditure-Tax-Treatment-of-Product-Registrations-Trade-Marks-and-Regulatory-Approvals-1024x536.jpg 1024w, https://bhattandjoshiassociates.com/wp-content/uploads/2026/11/Capital-vs-Revenue-Expenditure-Tax-Treatment-of-Product-Registrations-Trade-Marks-and-Regulatory-Approvals-768x402.jpg 768w, https://bhattandjoshiassociates.com/wp-content/uploads/2026/11/Capital-vs-Revenue-Expenditure-Tax-Treatment-of-Product-Registrations-Trade-Marks-and-Regulatory-Approvals.jpg 1200w" sizes="(max-width: 1511px) 100vw, 1511px" /></p>
<p dir="ltr">A pharmaceutical manufacturer closes its books for the year with three payments recorded on the same page of its ledger. The question of whether these payments constitute capital or revenue expenditure under income tax law determines whether they can be deducted against current profits or must be capitalised and potentially depreciated. The first is a fee paid to a foreign drug regulator, together with the cost of assembling the dossier of stability, bioequivalence and manufacturing data that the regulator insists upon, so that a medicine the company has been making for years may lawfully be sold in that country. The second is the fee paid to the Trade Marks Registry to register in India the brand name under which that medicine is sold. The third is a lump sum paid to an unconnected company for the exclusive right to use its well-known mark on a different product line for the next ten years.</p>
<p dir="ltr">Each of the three buys something that will outlast the year in which it was paid. If endurance were the whole of the enquiry, all three would be capital expenditure and none of them deductible against this year&#8217;s profits. The law is not so simple, and the difference between the three characterisations is worth a great deal more than the payments themselves. What follows examines the distinction between capital vs revenue expenditure under income tax law, how the courts have drawn the line, where the position is reasonably clear, and where &#8211; in the case of product registrations and regulatory approvals &#8211; it has not yet been drawn at all.</p>
<h2><strong>Capital vs Revenue Expenditure under Section 37(1)</strong></h2>
<p dir="ltr">Section 37(1) of the Income-tax Act, 1961 is the residual provision for business deductions. It allows expenditure &#8211; not of the nature described in sections 30 to 36, and “not being in the nature of capital expenditure or personal expenses of the assessee” &#8211; laid out wholly and exclusively for the purposes of the business. Capital expenditure is shut out. That is not always fatal, because if the outlay has produced an asset of a recognised class the assessee falls back on depreciation: since the Finance (No. 2) Act, 1998, section 32(1)(ii) has covered intangible assets &#8211; “know-how, patents, copyrights, trade marks, licences, franchises or any other business or commercial rights of similar nature” &#8211; acquired on or after 1 April 1998, depreciable at 25 per cent on the written-down value of the block. But where no asset of any recognised class results, a finding of capital means the deduction is lost altogether. That is why the primary characterisation is fought so hard, and why the fallback contest over the residuary words matters almost as much.</p>
<h2 dir="ltr"><strong>The Enduring Benefit Test, And The Qualification That Rescued It</strong></h2>
<p>The enduring benefit test is one of the principal judicial tests for determining whether expenditure constitutes capital expenditure or revenue expenditure under income tax law. <span style="font-size: 15px; letter-spacing: -0.015em; text-transform: initial;">The classical formulation is Assam Bengal Cement Co. Ltd. v. CIT [1955] 27 ITR 34 (SC), decided on 11 November 1954. A cement company holding a twenty-year limestone lease agreed to pay the State annual “protection fees” in return for an undertaking that no competing lease would be granted in the area. Bhagwati J. stated the test quoted ever since: if the expenditure is made for acquiring or bringing into existence an asset or advantage for the enduring benefit of the business it is attributable to capital; if it is made not for that purpose but for running the business with a view to producing profits, it is revenue. The formulation descends from Viscount Cave L.C. in Atherton v. British Insulated and Helsby Cables Ltd. [1925] 10 Tax Cas. 155. Note that the fees were held capital although payable annually rather than once and for all: the aim and object of the expenditure, not its periodicity, determines its character, and the advantage bought &#8211; freedom from competition &#8211; attached to the capital asset itself.</span></p>
<p dir="ltr">Left there, the test would have swallowed the deduction, since almost every business payment yields some benefit beyond the year. The correction came in Empire Jute Co. Ltd. v. CIT [1980] 124 ITR 1 (SC), decided on 9 May 1980, where a jute mill had bought “loom hours” from other members of its trade association so as to work its looms for longer than its own allotment permitted. Bhagwati J. held that the test of enduring benefit “is not a certain or conclusive test and it cannot be applied blindly and mechanically”. What matters is the field in which the advantage lies: only where it is in the capital field is the expenditure disallowable, and where it consists merely in facilitating the assessee&#8217;s trading operations or enabling the business to be carried on more efficiently while leaving the fixed capital untouched, the expenditure is on revenue account even though the advantage may endure indefinitely. The Court considered Lord Haldane&#8217;s fixed-and-circulating capital distinction in John Smith &amp; Son v. Moore (1921) 12 Tax Cas. 266 and declined to decide the case on it: Empire Jute is authority against the sufficiency of any single test, and is misused when cited for that dichotomy rather than for the limits of it.</p>
<p dir="ltr">The applications run both ways. In Bikaner Gypsums Ltd. v. CIT [1991] 187 ITR 39 (SC), decided on 23 October 1990, a sum paid to shift a railway station obstructing mining operations was revenue: the payment removed an obstruction and no capital asset was acquired. In CIT v. Madras Auto Service (P.) Ltd. [1998] 233 ITR 468 (SC) the cost of reconstructing a building on leased premises was revenue, the building belonging to the lessor from the moment it was built, so that what the assessee obtained was a long tenure at a concessional rent rather than an asset. In Alembic Chemical Works Co. Ltd. v. CIT [1989] 177 ITR 377 (SC) a lump sum for know-how improving the yield of an existing process was revenue, there being no new plant and no new line of business. The contrary case is Honda Siel Cars India Ltd. v. CIT [2017] 395 ITR 713 (SC), where a technical collaboration fee was capital precisely because there was no existing business, the agreement having brought a new manufacturing unit into existence; it must be cited with its sequel at [2018] 409 ITR 42 (SC), allowing depreciation on the capitalised sum. Apportionment between the two accounts was sanctioned in Jonas Woodhead &amp; Sons (India) Ltd. v. CIT [1997] 224 ITR 342 (SC), but that decision is fact-specific.</p>
<h2><strong>Trade Mark Registration Expenses: Capital or Revenue Expenditure?</strong></h2>
<p dir="ltr">On trade marks the oldest authority still governs. In CIT v. Finlay Mills Ltd. [1951] 20 ITR 475 (SC), decided on 1 October 1951, expenditure on the first registration of trade marks was held revenue and allowable under section 10(2)(xv) of the Indian Income-tax Act, 1922, the predecessor of section 37(1). Registration brings no new asset into existence: the mark and its reputation exist already, built up by trading, and registration supplies only a better and cheaper means of protecting what the trader has. The Revenue was the appellant, so the case is CIT v. Finlay Mills and not the reverse; it is frequently mis-styled.</p>
<p dir="ltr">The same reasoning governs payment for the use of a mark the payer will never own. In Hilton Roulunds Ltd. v. CIT [2018] 304 CTR 721 / [2019] 412 ITR 436 (Delhi) a lump sum of Rs. 1 crore for the exclusive right to use the “HILTON” mark was held revenue: the assessee never became owner, it had permission to use, and neither the lump-sum form of the payment nor the duration of the right was decisive &#8211; ownership was. Contrast the outright acquisition of a registered mark, which is an accretion to the profit-making apparatus and is capital; but since assessment year 1999-2000 the consequence is depreciation at 25 per cent rather than disallowance. A caution on a case often pressed into service here: CIT v. Ciba of India Ltd. [1968] 69 ITR 692 (SC) is not authority that periodical payments for the use of trade marks are revenue, because the trade-mark royalty there was allowed by the Income-tax Officer and was never in dispute; what the Court characterised were the technical-consultancy and research-materials contributions under a terminable five-year non-exclusive agreement, which gave “merely the right to draw upon the technical knowledge&#8230; for a limited period”.</p>
<h2><strong>Product Registration Expenses: Capital or Revenue Expenditure?</strong></h2>
<p dir="ltr">Before a medicine, an agrochemical or a medical device may be sold in a foreign market, the manufacturer must register it with the national regulator: a dossier of stability data, bioequivalence studies, site and process information and proposed labelling is filed, a fee is paid, and an annual maintenance fee usually follows. In the United States the vehicle for a generic medicine is an abbreviated new drug application; in the European Union, a marketing authorisation. The permission attaches to a particular product made at a particular site, and may be suspended or withdrawn. The sums are substantial and recur with every new territory.</p>
<p dir="ltr">The assessee&#8217;s case is that no asset is acquired. The product already exists and is already manufactured; the registration removes a legal impediment to selling it in one more market, and is a condition of trading rather than an addition to the apparatus with which the trade is carried on. Empire Jute is said to be directly in point, with Bikaner Gypsums and Madras Auto Service for the proposition that clearing an obstruction or satisfying a regulator produces no capital asset, and Finlay Mills for the analogous proposition that registering what one already has is not the acquisition of something new. The Revenue&#8217;s case deserves to be stated with equal care. A product registration is a licence in terms, and licences are among the intangibles enumerated in section 32(1)(ii); it has independent commercial value, dossiers being bought and sold with product portfolios; it endures for years; and it opens a market that was legally closed, which is an expansion of the profit-earning apparatus rather than a more efficient use of the existing one &#8211; a distinction Empire Jute itself draws.</p>
<p dir="ltr">The Revenue can also point to CIT v. Bharti Hexacom Ltd., 2023 INSC 917 = [2023] 458 ITR 593 (SC), decided on 16 October 2023 with review dismissed at [2024] 297 Taxman 368 (SC), where the variable annual licence fee under the New Telecom Policy, 1999, computed as a percentage of adjusted gross revenue and paid year by year, was nevertheless held capital and amortisable under section 35ABB. If a recurring, revenue-linked payment for permission to operate is capital, why should a filing fee for permission to sell be revenue? The answer is that the question is open and the analogy weaker than it appears: section 35ABB already assumes a telecom licence fee to be capital and supplies the amortisation, so the Court&#8217;s task was only to decide whether the 1999 policy split the fee, and there is no equivalent provision for a drug or agrochemical registration. What exists is a consistent line of Tribunal decisions treating foreign product-registration expenditure as revenue on Empire Jute reasoning, of which ACIT v. Sharda Cropchem Ltd. (ITAT, Mumbai, order dated 21 January 2025) is a recent example. No High Court or Supreme Court has settled whether foreign product registration charges are capital or revenue expenditure, and the issue stands admitted as a substantial question of law in departmental appeals before the Gujarat High Court. Anyone advising on it today is therefore advising on an unsettled question.</p>
<h2 dir="ltr"><strong>Where The Statute Supplies Its Own Answer</strong></h2>
<p dir="ltr">For certain approvals Parliament has removed the argument by legislating a write-off. Section 35ABB, inserted by the Finance Act, 1997 with retrospective effect from 1 April 1996, spreads capital expenditure actually paid for a licence to operate telecommunication services over the unexpired period of the licence; section 35ABA, inserted by the Finance Act, 2016 with effect from 1 April 2017, does the same for spectrum fees. Section 35D spreads specified preliminary expenses over five years, the fees for registering the company appearing at clause (2)(c)(iii) &#8211; the prospectus and public-issue costs are at clause (2)(c)(iv), and the two are frequently transposed in commentary. Historically section 35A spread the cost of patent rights and copyrights over fourteen years and section 35AB spread lump-sum know-how payments over six; both were closed by the Finance (No. 2) Act, 1998, precisely because the same subject matter had moved into the depreciation scheme. The pattern cuts both ways: where Parliament has addressed a class of approval it has treated the outlay as capital and supplied an amortisation, which is a respectable analogy for the Revenue; the assessee answers that the absence of any such provision for product registrations suggests Parliament never regarded them as creating an asset.</p>
<h2 dir="ltr"><strong>How Wide Are “Business Or Commercial Rights Of Similar Nature”?</strong></h2>
<p dir="ltr">Because a finding of capital expenditure so often shifts the fight to section 32(1)(ii), the width of its closing words repays attention. In Techno Shares &amp; Stocks Ltd. v. CIT [2010] 327 ITR 323 (SC) a Bombay Stock Exchange membership card was held to be a licence, or a right akin to one, and therefore depreciable &#8211; but the Court confined the judgment strictly to that right in the assessment years before it and said in terms that it should not be understood to mean that every business or commercial right would constitute a licence or a franchise for the purposes of the section, expressly leaving open whether goodwill is depreciable. In Areva T&amp;D India Ltd. v. Deputy CIT [2012] 345 ITR 421 (Delhi) a bundle of intangibles acquired on a slump sale fell within the residuary words; the reasoning is noscitur a sociis rather than a restrictive application of ejusdem generis, the residuary items needing not to answer the description of the enumerated ones but to share with them the genus of being tools of the trade. Commentary sometimes reports Areva as having held goodwill depreciable; it did not decide goodwill. Goodwill itself was held depreciable in CIT v. Smifs Securities Ltd. [2012] 348 ITR 302 (SC) for assessment year 2003-04, on a short order resting on unchallenged concurrent findings, and that holding was legislatively reversed by the Finance Act, 2021 from assessment year 2021-22; the decision should never be cited without stating the assessment year.</p>
<p dir="ltr">The most significant recent development is Sharp Business System v. CIT-III, 2025 INSC 1481 (SC), decided on 19 December 2025. A joint venture had paid Rs. 3 crore to its Indian partner for a seven-year covenant not to compete. The Delhi High Court had held the payment capital and had gone on to refuse depreciation as well, reasoning that the residuary words presuppose a right enforceable in rem whereas a negative covenant is a right only in personam ([2012] 27 taxmann.com 50 / 254 CTR 233 (Delhi)). The Supreme Court reversed: the payment was revenue and deductible under section 37(1), it merely enabled the business to be carried on more efficiently and profitably, it added nothing to the profit-earning apparatus, a negative covenant confers no ownership of any transferable or exploitable right, and the duration of the restraint was not determinative. Because the Court held the payment revenue it did not adjudicate depreciation at all and remanded the contrary High Court line, so the “right in rem” reasoning no longer stands as authority and whether a non-compete covenant is a depreciable intangible is presently open. More broadly, the Court has re-centred the enquiry where Empire Jute placed it: not on how long the advantage lasts, but on whether anything was added to the apparatus with which profits are earned.</p>
<h2 dir="ltr"><strong>The Position By Period</strong></h2>
<div dir="ltr">
<table>
<thead>
<tr>
<th scope="col">Effective from</th>
<th scope="col">Treatment of intangibles, licences and approvals</th>
<th scope="col">Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to AY 1995-96</td>
<td>No class of depreciable intangible assets. Know-how written off over six years under s.35AB (from AY 1986-87); patent rights and copyrights over fourteen years under s.35A. A purchased trade mark or commercial right yields neither a deduction under s.37(1) nor depreciation.</td>
<td>ss. 35A, 35AB</td>
</tr>
<tr>
<td>AY 1996-97</td>
<td>Capital expenditure actually paid for a licence to operate telecommunication services becomes amortisable over the unexpired period of the licence.</td>
<td>s.35ABB, inserted by the Finance Act, 1997 with retrospective effect from 1 April 1996</td>
</tr>
<tr>
<td>AY 1999-2000</td>
<td>Intangible assets &#8211; know-how, patents, copyrights, trade marks, licences, franchises or any other business or commercial rights of similar nature &#8211; acquired on or after 1 April 1998 become depreciable at 25 per cent. ss. 35A and 35AB closed for the future.</td>
<td>s.32(1)(ii), inserted by the Finance (No. 2) Act, 1998 w.e.f. 1 April 1999</td>
</tr>
<tr>
<td>AY 2003-04 to AY 2020-21</td>
<td>Goodwill arising on amalgamation held to be an asset within Explanation 3(b) to s.32(1), and therefore depreciable.</td>
<td>CIT v. Smifs Securities Ltd. [2012] 348 ITR 302 (SC)</td>
</tr>
<tr>
<td>AY 2017-18</td>
<td>Spectrum fee becomes amortisable on the s.35ABB pattern, sub-sections (2) to (8) of that section applying mutatis mutandis.</td>
<td>s.35ABA, inserted by the Finance Act, 2016 w.e.f. 1 April 2017</td>
</tr>
<tr>
<td>AY 2021-22</td>
<td>Goodwill removed from the depreciable intangibles in s.32(1)(ii) and from the definition of block of assets; consequential changes to ss. 43(6)(c), 50 and 55(2)(a); Rule 8AC supplies the transition.</td>
<td>Finance Act, 2021; Rule 8AC, Notification No. 77/2021 dated 7 July 2021</td>
</tr>
<tr>
<td>Tax year 2026-27</td>
<td>Recodification without substantive change. General deduction s.34; depreciation s.33, intangibles at s.33(1)(b) in identical words; actual cost s.39; preliminary expenses s.44; telecom licence and spectrum fees consolidated in the table to s.52. ss. 35A and 35AB not re-enacted.</td>
<td>Income-tax Act, 2025, in force 1 April 2026</td>
</tr>
</tbody>
</table>
</div>
<h2 dir="ltr"><strong>Under The Income-tax Act, 2025</strong></h2>
<p dir="ltr">The Income-tax Act, 2025 came into force on 1 April 2026 and recodifies this area without rewriting it. The general deduction, formerly section 37(1), is now section 34, which preserves the exclusion of expenditure “in the nature of capital expenditure or personal expenses of the assessee”, the old Explanations being promoted into operative sub-sections. Depreciation, formerly section 32, is section 33, and section 33(1)(b) reproduces the intangibles limb verbatim, retaining the 1 April 1998 acquisition threshold, the closing genus and the goodwill carve-out, which appears again in the definition of “block of assets” in section 2(17)(b); the rate of 25 per cent is preserved by Part B of Appendix I to the Income-tax Rules, 2026. Actual cost is section 39, preliminary expenses section 44, and the telecom licence and spectrum fee provisions are consolidated into the table to section 52; sections 35A and 35AB are not re-enacted, having long been spent.</p>
<p data-pm-slice="1 1 []">Because the operative language remains unchanged, the case law discussed above continues to apply to the determination of capital or revenue expenditure under the Income-tax Act, 2025. Two cautions are nevertheless in order. The Act uses the expression “tax year”, defined in section 3(1) as the twelve months of the financial year commencing on 1 April, replacing the previous-year and assessment-year distinction. The renumbering also requires care: under the 2025 Act, section 32 is “Other deductions”, section 33 deals with depreciation, section 34 provides for the general deduction, and section 37 contains the actual-payment rule corresponding to section 43B of the 1961 Act. A reference to “section 37(1)” without identifying the applicable Act is therefore genuinely ambiguous.</p>
<h2 dir="ltr"><strong>Where The Line Falls</strong></h2>
<p dir="ltr">Four propositions emerge. Duration is not the test: an advantage may endure indefinitely and the payment still be revenue, as Empire Jute and now Sharp Business System both hold. An outlay that removes an obstacle to trading, satisfies a condition of trading, or protects what the trader already has is ordinarily revenue &#8211; the thread running through Bikaner Gypsums, Madras Auto Service and Finlay Mills. An outlay that buys a right the payer will own, and could in principle sell, is ordinarily capital, but for assets acquired on or after 1 April 1998 the consequence is depreciation rather than disallowance, so the argument has shifted from whether anything is allowed to which provision allows it. And where Parliament has legislated a specific amortisation, the statute closes the argument.</p>
<p dir="ltr">None of this is a settled victory for the assessee. Assam Bengal Cement remains good law where an outlay really does buy freedom from competition attaching to a capital asset; Honda Siel shows that a collaboration fee paid before any business exists is capital however it is dressed up; Bharti Hexacom shows that a recurring, revenue-linked payment can still be capital where what is bought is the right to operate at all. The unresolved margin is occupied by product registrations and regulatory approvals, which have the legal form of a licence and the commercial function of a condition of trading, and on which the Tribunal&#8217;s consistent view awaits testing. Until it is tested, the prudent course for an assessee is to document what the expenditure did not obtain &#8211; that no ownership passed, that no new product or plant came into existence, that the approval is revocable &#8211; and for the Revenue to identify, with evidence rather than assertion, the asset it says was acquired.</p>
<h2 dir="ltr"><strong>Frequently Asked Questions</strong></h2>
<p dir="ltr"><strong>Is the fee for registering my own trade mark deductible in the year it is paid?</strong> Yes. CIT v. Finlay Mills Ltd. [1951] 20 ITR 475 (SC) holds that registering a trade mark brings no new asset into existence and only improves the means of protecting a reputation already built, so the fee is revenue. Buying a mark from someone else is different: that is capital, but since assessment year 1999-2000 it is depreciable at 25 per cent as an intangible asset under section 32(1)(ii).</p>
<p dir="ltr"><strong>If an expenditure is held to be capital, is the deduction simply lost?</strong> Not necessarily, but it can be. If the outlay has produced an asset within a recognised class &#8211; including the intangibles in section 32(1)(ii), now section 33(1)(b) of the 2025 Act &#8211; depreciation is available. If it has not, the deduction is lost entirely, because section 37(1) excludes capital expenditure and section 32 has nothing to attach to. Techno Shares warns that not every commercial right is a licence or a franchise for this purpose, and goodwill has been outside the section since assessment year 2021-22.</p>
<p dir="ltr"><strong>Are product registration charges paid to a foreign regulator revenue expenditure?</strong> The Tribunal has consistently said yes, on the footing that no asset is acquired and the registration merely permits an existing product to be sold in one more market; ACIT v. Sharda Cropchem Ltd. (ITAT, Mumbai, 21 January 2025) is a recent example. But no High Court or Supreme Court has decided the point, it is admitted as a substantial question of law in departmental appeals before the Gujarat High Court, and the Revenue&#8217;s contrary analogy is CIT v. Bharti Hexacom Ltd. [2023] 458 ITR 593 (SC). The position should be treated as unsettled.</p>
<h2 dir="ltr"><strong>Sources &amp; Citations</strong></h2>
<ul dir="ltr">
<li>Income-tax Act, 1961: ss. 32(1)(ii) and Explanation 3, 35A, 35AB, 35ABA, 35ABB, 35D(2)(c)(iii) and (iv), 37(1), 43(1), 43(6)(c), 50, 55(2)(a); Income-tax Rules, 1962, Appendix I Part B and Rule 8AC.</li>
<li>Amending Acts: Finance Act, 1985 (s.35AB); Finance Act, 1997 (s.35ABB, retrospective from 1 April 1996); Finance (No. 2) Act, 1998 (s.32(1)(ii) intangibles w.e.f. 1 April 1999; closure of ss. 35A and 35AB); Finance Act, 2016 (s.35ABA w.e.f. 1 April 2017); Finance Act, 2021 (goodwill excluded w.e.f. AY 2021-22); Rule 8AC inserted by Notification No. 77/2021 dated 7 July 2021.</li>
<li>Income-tax Act, 2025 (in force 1 April 2026): ss. 2(17), 3(1), 33, 34, 39, 44, 45, 52, 66; Income-tax Rules, 2026, Appendix I Part B.</li>
<li>Assam Bengal Cement Co. Ltd. v. CIT [1955] 27 ITR 34 (SC) = AIR 1955 SC 89, decided 11.11.1954 (Mahajan C.J., S.R. Das, N.H. Bhagwati and T.L. Venkatarama Ayyar JJ.).</li>
<li>Empire Jute Co. Ltd. v. CIT [1980] 124 ITR 1 (SC) = (1980) 4 SCC 25 = AIR 1980 SC 1946, decided 09.05.1980 (Bhagwati, Tulzapurkar and Pathak JJ.).</li>
<li>Atherton v. British Insulated and Helsby Cables Ltd. [1925] 10 Tax Cas. 155 (HL); John Smith &amp; Son v. Moore (1921) 12 Tax Cas. 266 (HL).</li>
<li>CIT v. Finlay Mills Ltd. [1951] 20 ITR 475 (SC) = AIR 1951 SC 464, decided 01.10.1951.</li>
<li>CIT v. Ciba of India Ltd. [1968] 69 ITR 692 (SC) = AIR 1968 SC 1131, decided 15.12.1967 (Shah, Ramaswami and Bhargava JJ.).</li>
<li>Alembic Chemical Works Co. Ltd. v. CIT [1989] 177 ITR 377 (SC) = (1989) 3 SCC 329, decided 31.03.1989.</li>
<li>Bikaner Gypsums Ltd. v. CIT [1991] 187 ITR 39 (SC) = (1991) 1 SCC 328, decided 23.10.1990.</li>
<li>Jonas Woodhead &amp; Sons (India) Ltd. v. CIT [1997] 224 ITR 342 (SC), decided 11.02.1997, affirming [1979] 117 ITR 55 (Mad.).</li>
<li>CIT v. Madras Auto Service (P.) Ltd. [1998] 233 ITR 468 (SC) = [1998] 99 Taxman 575, decided 12.08.1998 (Sujata V. Manohar and S. Rajendra Babu JJ.).</li>
<li>Techno Shares &amp; Stocks Ltd. v. CIT [2010] 327 ITR 323 (SC) = (2010) 9 SCC 410.</li>
<li>Areva T&amp;D India Ltd. v. Deputy CIT [2012] 345 ITR 421 (Delhi) = [2012] 20 taxmann.com 29, ITA No. 315 of 2010.</li>
<li>CIT v. Smifs Securities Ltd. [2012] 348 ITR 302 (SC) = [2012] 24 taxmann.com 222, decided 22.08.2012 (Kapadia C.J. and Madan B. Lokur J.), AY 2003-04.</li>
<li>Honda Siel Cars India Ltd. v. CIT [2017] 395 ITR 713 (SC), decided 09.06.2017 (A.K. Sikri and Ashok Bhushan JJ.), with the follow-on order at [2018] 409 ITR 42 (SC), decided 14.11.2018, allowing depreciation. Not to be confused with Honda Siel Power Products Ltd. v. CIT [2007] 295 ITR 466 (SC), a section 254(2) case concerning a different company.</li>
<li>Hilton Roulunds Ltd. v. CIT [2018] 304 CTR 721 / [2019] 412 ITR 436 (Delhi), decided 20.04.2018.</li>
<li>CIT v. Bharti Hexacom Ltd., 2023 INSC 917 = [2023] 458 ITR 593 (SC), decided 16.10.2023; review dismissed, [2024] 297 Taxman 368 (SC).</li>
<li>Sharp Business System v. CIT-III, 2025 INSC 1481 (SC), decided 19.12.2025, reversing Sharp Business System v. CIT-III [2012] 27 taxmann.com 50 / 254 CTR 233 (Delhi).</li>
<li>ACIT v. Sharda Cropchem Ltd. (ITAT, Mumbai), order dated 21.01.2025 &#8211; Tribunal authority only.</li>
</ul>
<h2><strong>Related Reading</strong></h2>
<ul>
<li>Is Goodwill an “Asset” for Depreciation? Smifs Securities and Explanation 3(b)</li>
<li>Goodwill Removed from Depreciable Assets: The Finance Act 2021, Its Transition and Its Fallout</li>
<li>Can Capital Gains Be Computed on Self-Generated Intangibles? The Section 55 Machinery Provision</li>
<li>Section 40(a)(ia) and the Small Transporter: Form 15-I, Form 15-J, and the Anatomy of a TDS Disallowance</li>
<li>Section 14A and Rule 8D: Disallowing Expenditure When There Is No Exempt Income</li>
</ul>
<p dir="ltr">© Bhatt &amp; Joshi Associates. This article is for general information and academic discussion only; it is not legal advice and must not be acted on without advice on the specific facts.</p>
<p>The post <a href="https://bhattandjoshiassociates.com/capital-vs-revenue-expenditure-tax-treatment-of-product-registrations-trade-marks-and-regulatory-approvals/">Capital vs Revenue Expenditure: Tax Treatment of Product Registrations, Trade Marks and Regulatory Approvals</a> appeared first on <a href="https://bhattandjoshiassociates.com">Bhatt &amp; Joshi Associates</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
